Aimmune Therapeutics (NASDAQ: AIMT) and Advanced Accelerator Applications (NASDAQ:AAAP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Aimmune Therapeutics and Advanced Accelerator Applications, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aimmune Therapeutics 0 0 2 0 3.00
Advanced Accelerator Applications 0 1 4 0 2.80

Aimmune Therapeutics currently has a consensus target price of $36.67, indicating a potential upside of 82.88%. Advanced Accelerator Applications has a consensus target price of $54.00, indicating a potential upside of 10.97%. Given Aimmune Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Aimmune Therapeutics is more favorable than Advanced Accelerator Applications.

Valuation and Earnings

This table compares Aimmune Therapeutics and Advanced Accelerator Applications’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics N/A N/A -$106.22 million ($2.25) -8.91
Advanced Accelerator Applications N/A N/A N/A ($0.68) -71.56

Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Aimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aimmune Therapeutics and Advanced Accelerator Applications’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics N/A -44.53% -42.00%
Advanced Accelerator Applications -29.01% -14.38% -9.65%

Volatility & Risk

Aimmune Therapeutics has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500. Comparatively, Advanced Accelerator Applications has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Insider and Institutional Ownership

72.9% of Aimmune Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Advanced Accelerator Applications shares are owned by institutional investors. 24.6% of Aimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Advanced Accelerator Applications Company Profile

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.